Dana Krueger

Dana is a trusted advisor to boards and CEOs across the global healthcare ecosystem, bringing more than 20 years of experience at the intersection of science, innovation, and enterprise leadership. She advises on CEO succession, board composition and effectiveness, and C-suite leadership bringing a particular depth in the biopharmaceutical industry.

Dana previously led Russell Reynolds Associates’ global Healthcare sector and Pharmaceuticals & Biotech practice as well as served as Head of Healthcare EMEAI. Her work is grounded in a deep understanding of governance, leadership judgment, and the evolving expectations placed on boards and executive teams in a purpose-led yet volatile and fast-moving environment.

In addition to her client work, Dana is currently a member of the firm’s Senior Leadership Team as Chair of Blueprint 2035, which defines the long-term evolution of the firm to ensure RRA remains distinctive and trusted in a changing leadership landscape. Earlier, she served as Global Co-Head of Capabilities and on the firm’s Executive Committee.

Prior to joining Russell Reynolds Associates, Dana held leadership roles in the life sciences practice at the Monitor Group (now Monitor Deloitte). She began her career as a post-doctoral fellow at Harvard University and was a Fulbright fellow at the University of Sydney.